TVRD · Tvardi Therapeutics, Inc.
$1.82
+0.02 (+1.11%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that its present capital resources as of June 30, 2026 will not be sufficient to fund its planned operations for at least one year from the issuance date of the unaudited condensed consolidated financial statements, included elsewhere in this Quarterly Report, which raises substantial doubt as to our ability to continue as a going concern. We plan to seek additional funding through equity offerings, including through our ATM Facility, or debt financings, credit or loan facilities, strategic alliances and licensing arrangements. However, there can be no assurance that such funding will be available to us, will be obtained on terms favorable to us, or will provide us with sufficient funds to meet our objectives.”View the 10-Q filed Aug 14, 2026
Market Cap
$24.28M
Shares
13.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.14M
-66%
FY2024
Net Income
-$18.21M
+38%
FY2025
Gross Margin
100%
FY2021
Operating Margin
-393.82%
+185.6pp
FY2024
Diluted EPS
-$3.26
+71.5%
FY2025
Operating Cash Flow
-$23.5M
-28.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.57M | — | $7.14M | $20.97M | $41.87M | $23.03M | $135.08M | $19.89M | $13.47M | $911K | $86K | $3.8M | $3.18M | $11.96M | $1.19M | |
| — | — | — | — | — | $0 | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $23.03M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | 100% | — | — | — | — | — | — | — | — | — | |
| $18.01M | $18.01M | $23.65M | $108.51M | $91.88M | $82.7M | $107.85M | $113.82M | $75.53M | $48.52M | $49.25M | $21.22M | $15.07M | $8.69M | $4.6M | |
| $9.2M | $8.74M | $4.46M | $27.78M | $30.26M | $29.41M | $21.85M | $17.75M | $15.32M | $11.87M | $9.23M | $7.77M | $6.18M | $3.52M | $2.83M | |
| $95K | $95K | $95K | $259K | $248K | $248K | $209K | $198K | $370K | $495K | $1.47M | $839K | $783K | $789K | $1.02M | |
| $3.16M | — | $5.57M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $27.21M | $26.75M | $28.11M | $142.46M | $129.4M | $112.11M | $129.7M | $131.57M | $90.85M | $60.4M | $58.49M | $28.99M | $21.25M | $12.2M | $7.43M | |
| -$27.21M | -$26.75M | -$28.11M | -$121.5M | -$87.54M | -$89.08M | $5.39M | -$111.68M | -$77.38M | -$59.49M | -$58.4M | -$25.19M | -$18.07M | -$237K | -$6.24M | |
| — | — | -393.82% | -579.43% | -209.08% | -386.85% | 3.99% | -561.6% | -574.52% | -6529.64% | -67906.98% | -662.32% | -568.84% | -1.98% | -524.03% | |
| -$27.11M | -$26.65M | -$28.01M | -$121.24M | -$87.29M | -$88.84M | $5.59M | -$111.48M | -$77.01M | -$58.99M | -$56.94M | -$24.35M | -$17.29M | $552K | -$5.22M | |
| — | $700K | $700K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $7.16M | -$2.04M | $3.59M | $2.06M | $642K | $2.33M | $4.49M | $2.98M | $1.16M | $652K | $101K | $126K | -$3.76M | — | |
| — | — | -$71.27M | -$118.51M | -$85.47M | -$88.44M | $7.72M | -$107.19M | -$74.4M | -$58.33M | -$57.75M | -$25.09M | -$17.95M | -$3.99M | -$6.3M | |
| — | $0 | $0 | $0 | $0 | $0 | -$691K | -$816K | -$389K | -$204K | -$468K | -$397K | -$201K | -$30K | -$31K | |
| -$26.06M | -$18.21M | -$29.4M | -$118.51M | -$85.47M | -$88.44M | $8.41M | -$106.37M | -$74.01M | -$58.13M | -$57.28M | -$24.69M | -$17.75M | -$3.96M | -$6.27M | |
| — | — | -411.9% | -565.21% | -204.16% | -384.06% | 6.23% | -534.91% | -549.51% | -6380.35% | -66604.65% | -649.22% | -558.55% | -33.12% | -526.97% | |
| -$26.06M | -$18.21M | -$29.4M | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$26.05M | -$18.21M | -$29.4M | -$117.1M | -$86.79M | -$88.87M | $8.31M | -$106.09M | -$74.06M | -$58.2M | -$57.24M | -$24.73M | -$17.75M | -$3.07M | — | |
| USD/shares | -$0.67 | -$2.46 | -$11.42 | -$78.78 | -$57.36 | -$62.64 | $6.48 | -$89.64 | -$74.16 | — | — | — | — | — | — |
| USD/shares | $0.04 | -$3.26 | -$11.42 | -$78.78 | -$57.36 | -$62.64 | $6.48 | -$89.64 | -$74.16 | — | — | — | — | — | — |
| shares | — | 7.42M | 2.57M | 1.5M | 1.49M | 1.41M | 1.32M | 1.19M | 997.02K | 866.75K | 757.75K | 683.9K | 582.39K | 114.81K | 91.67K |
| shares | — | 7.78M | 2.57M | 1.5M | 1.49M | 1.41M | 1.33M | 1.19M | 997.02K | 866.75K | 757.75K | 683.9K | 582.39K | 114.81K | 91.67K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.74×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.89×
Peer medians compare against the 246 similar-size Biotechnology companies (of 524 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Other Revenue | $4,327,000 | $699,000 | — | — | — | — | — |
| Other Revenue Noncash | $4,327,000 | $699,000 | — | — | — | — | — |
| Collaborative Revenue | $2,086,000 | $12,936,000 | $16,572,000 | $706,000 | — | — | — |
| Commercial Supply Revenue | $640,000 | $5,843,000 | $10,223,000 | $701,000 | — | — | — |
| Clinical Compound Revenue | $84,000 | $165,000 | — | $398,000 | $643,000 | $140,000 | $33,000 |
| License and Milestone Fees | — | $910,000 | $15,000,000 | $21,223,000 | $134,439,000 | $19,746,000 | $13,436,000 |
| Royalty | — | $415,000 | $72,000 | — | — | — | — |
Key facts
CIK
1346830
CUSIP
140755307
13F (30d)
47 filings
47 filers
Visit website
Investor relations